Apotex acquires US rights to PROVIGIL® (modafinil) and NUVIGIL® (armodafinil)
Feb 5, 2025TORONTO, Jan. 9, 2025 /CNW/ - Apotex Inc. ("Apotex"), the largest Canadian-based pharmaceutical company, today announced that its affiliate Nuvo Pharmaceuticals (Ireland) DAC has acquired the United States rights to PROVIGIL (modafinil) and NUVIGIL (armodafinil). PROVIGIL and NUVIGIL become the latest branded medicines to be sold in the United States within the Apotex Group's diversified global portfolio of more than 550 generic and branded prescription, over the counter and biosimilar product families across all major therapeutic areas.
PROVIGIL and NUVIGIL each improve wakefulness in patients with excessive sleepiness associated with narcolepsy, obstructive sleep apnea or shift work sleep disorder, and are prescribed by psychiatrists, endocrinologists, internists, sleep specialists, and primary care physicians.
"Acquiring the US rights to PROVIGIL and NUVIGIL marks a strategic milestone for Apotex and a significant initial step in growing our US specialty business, building upon the recent achievement of similar specialty transactions in Canada and advancing our Journey of Health growth strategy," said Allan Oberman, Apotex's President & CEO. "These acquisitions further reinforce our long-term commitment to improving patient care and continuing to expand our presence in the US."
"PROVIGIL and NUVIGIL address critical needs for patients experiencing excessive sleepiness. Leveraging our world-class commercial team, established distribution networks, and expertise in the US market, we are well-positioned to ensure these medications continue to reach patients effectively," said Christine Baeder, President of Apotex Corp., Apotex's US affiliate.
About PROVIGIL and NUVIGIL
PROVIGIL and NUVIGIL are indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy, obstructive sleep apnea (OSA), or shift work disorder. More information on PROVIGIL is available here. More information on NUVIGIL is available here.
About Apotex
Media inquries
Have a question for our media team? Fill out our inquiries form, and we’ll get back to you as soon as possible.
Latest news
-
May 25, 2025
Apotex launches nilotinib capsules, the first generic version of Tasigna®¹ in the United States, with 180 days of exclusivity
Nilotinib is a kinase inhibitor indicated to treat certain types of leukemia, including newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia ("Ph+ CML") in chronic phase in adults and children aged 1 year and older. It is also indicated for adults and pediatric patients with chronic or accelerated phase Ph+ CML with resistance or intolerance to prior therapy, demonstrating higher efficacy compared with other available treatments.
-
May 20, 2025
Apotex publishes 2024 Sustainability Report, highlighting progress and achievements in environmentally sustainable manufacturing, responsible business practices, and social impact
Apotex's 2024 Sustainability Report underscores our commitment to advancing health and unlocking new possibilities through partnerships, while championing sustainability and responsible business practices. "As we continue to execute our Journey of Health growth strategy, our focus on sustainability ensures that we are meeting the needs of patients, physicians, and pharmacists, and contributing positively to the environment and society. This report reflects our dedication to these values, and to transparency, accountability, and long-term value creation," said Allan Oberman, President & CEO, Apotex.
-
May 9, 2025
Apotex introduces IVRA™ (Melphalan) hydrochloride injection: First ready to dilute liquid formulation of Melphalan injection approved via 505(b)(2) NDA in the United States
Weston, Florida (May 09, 2025) – Apotex Corp. today launched IVRA™ (Melphalan) hydrochloride injection 90mg/ml multidose vial ("IVRA"), first ready-to-dilute liquid formulation of Melphalan injection approved via 505(b)(2) NDA in the United States.